Balfour Sartor, MD
University of North Carolina School of Medicine
Chapel Hill, NC

Midgett Distinguished Professor of Medicine
Professor Microbiology & Immunology
UNC Multidisciplinary Center for IBD Research and Treatment Director
Center for Gastrointestinal Biology and Disease Co-Director
Chief Medical Advisor, Crohn’s and Colitis Foundation of America
Clinical/Research Interests
Crohn's disease, ulcerative colitis, inflammatory bowel diseases (IBD), bacterial- host interactions, genetic regulation of commensal enteric bacteria.

University of North Carolina School of Medicine
Departments of medicine, Microbiology and Immunology

Our long term goals are to better define mechanisms of chronic intestinal inflammation and to identify areas for therapeutic intervention. Research in our laboratories is in the following four general areas.

Induction and perpetuation of chronic intestinal and extraintestinal inflammation by resident intestinal bacteria and their cell wall polymers:

We are exploring the hypothesis that normal luminal bacteria can induce immune-mediated chronic inflammation in the genetically susceptible host. We demonstrated that germ free (sterile) HLA-B27 transgenic rats, IL-10 knock out and IL-2 knock out mice fail to develop colitis, and that colitis develops within one week of colonization with specific pathogen free bacteria in these genetically engineered hosts. Moreover, all bacteria do not have equal capacities to induce inflammation, since Bacteroids vulgatus induces aggressive colitis in HLA-B27 transgenic rats, E. coli do not cause any inflammation and Lactobacilli is protective.

Mechanisms of genetically determined host susceptibility to bacterial products:

We demonstrated differential host genetic susceptibility to chronic inflammation in inbred rat strains using these experimental models of inflammation and are now exploring mechanisms of differential immunoregulation in these rat strains, concentrating on cytokine profiles and the kallikrein-kinin pathway.

Regulation of immunosuppressive molecules in intestinal epithelial cells:

We are investigating the in vivo regulation of intracellular IL-1 receptor antagonist (ic IL-1 RA) and the IkB/NFkB complex regulation of these molecules in epithelial cell lines. We have demonstrated altered IkBa degradation in intestinal epithelial cells and are exploring mechanisms of this delayed, incomplete degradation. Biologic importance of these inhibitors are examined by selective pharmacologic and molecular blockade and over expression of these molecules (i.e. dominant negative constructs and antisense oligonucleotides).

Performing clinical trials of novel therapeutic agents in inflammatory bowel disease patients:

We are investigating selective inhibitors such as rh IL-10 and anti-TNFa mAB in Crohn's disease patients and antibiotics and probiotic cocktails in ulcerative colitis patients.

Content available soon!

Content available soon!

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    eMonograph

    GI Alliance Payer Summit

    view details >

    Clinical and Managed Care Perspectives in Inflammatory Bowel Disease: Closing the Gap

    view details >

    Addressing Health Outcomes and Rising Costs in the Management of Inflammatory Bowel Disease

    view details >

    The Guide to Guidelines in IBD: Interpretation and Appropriate Use in Clinical Practice

    view details >

    INFORM UC: An Update on Contemporary Management of UC

    view details >

    Breaking The Barriers: Improving Access to Biologic Therapies in IBD

    view details >

    IBD Management: State of the Art in 2018

    view details >

    Improving IBD Care A Personalized Approach to Management

    view details >

    Expert Perspectives in the Management of Inflammatory Bowel Disease (IBD): A Review of Recent Advances

    view details >

    Advances in IBD

    view details >

    Optimizing the Management of Inflammatory Bowel Disease

    view details >

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon

    Audiocasts

    Content available soon!

    Content available soon!

    © Copyright 2013-2024 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.